Biosimulation Market Overview

The global biosimulation market is experiencing rapid growth as pharmaceutical and biotechnology companies increasingly adopt computational modeling technologies to improve drug discovery, reduce development costs, and enhance clinical success rates. The market is projected to grow from USD 4.27 billion in 2026 to USD 9.24 billion by 2031, registering a strong CAGR of 16.7% during the forecast period.

The growing complexity of drug development, increasing research and development (R&D) investments, and rising regulatory acceptance of model-informed approaches are accelerating the adoption of biosimulation solutions worldwide. Advanced technologies such as Physiologically Based Pharmacokinetic (PBPK) modeling, Quantitative Systems Pharmacology (QSP), Population PK/PD modeling, and Model-Informed Drug Development (MIDD) are enabling researchers to make faster, more informed decisions throughout the drug development lifecycle.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=838

What Is Biosimulation?

Biosimulation refers to the use of advanced mathematical models and computer simulations to predict how drugs interact with biological systems. These technologies integrate biological, pharmacological, and clinical data to evaluate drug behavior before extensive laboratory or clinical testing.

Biosimulation supports multiple stages of pharmaceutical development, including:

• Drug candidate selection
• Dose optimization
• Drug-drug interaction prediction
• Clinical trial design
• Safety and efficacy evaluation
• Regulatory submissions
• Personalized medicine strategies

By reducing uncertainty and improving predictive accuracy, biosimulation helps pharmaceutical companies shorten development timelines while lowering costs.

Key Drivers Fueling Biosimulation Market Growth

Rising Complexity of Drug Discovery

Developing innovative therapies has become increasingly complex due to growing scientific understanding of disease biology and personalized medicine.

Modern drug development requires sophisticated computational models capable of predicting pharmacokinetics, pharmacodynamics, toxicity, and treatment outcomes before entering costly clinical trials.

Biosimulation enables researchers to evaluate multiple development scenarios virtually, helping identify the most promising drug candidates earlier in the process.

Increasing Pharmaceutical R&D Investments

Global pharmaceutical companies continue investing heavily in research and development to address unmet medical needs across oncology, rare diseases, immunology, neuroscience, and infectious diseases.

As R&D costs continue rising, organizations are seeking technologies that improve efficiency and maximize the probability of clinical success.

Biosimulation platforms help optimize development strategies while reducing unnecessary laboratory experiments and failed clinical trials.

Request For Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=838

Growing Adoption of Model-Informed Drug Development (MIDD)

Model-Informed Drug Development is becoming an essential component of modern pharmaceutical research.

MIDD combines computational modeling with experimental and clinical data to support evidence-based decisions throughout drug development.

Its applications include:

• Dose selection
• Pediatric extrapolation
• Clinical trial optimization
• Regulatory decision support
• Exposure-response analysis
• Drug interaction assessment

As global regulatory agencies increasingly encourage model-informed approaches, adoption of biosimulation software continues to expand.

Regulatory Agencies Supporting Biosimulation

Regulatory acceptance has become one of the strongest growth drivers for the biosimulation industry.

The US Food and Drug Administration (FDA) has increasingly recognized the value of Physiologically Based Pharmacokinetic (PBPK) modeling in regulatory submissions, particularly for predicting drug-drug interactions and supporting dosing recommendations.

Additionally, the International Council for Harmonisation (ICH) introduced the M15 Guideline on Model-Informed Drug Development, providing greater consistency and encouraging broader adoption of computational modeling across global pharmaceutical development.

These initiatives are increasing confidence in biosimulation technologies among pharmaceutical companies and regulatory authorities alike.

Artificial Intelligence Accelerating Biosimulation

Artificial intelligence and machine learning are transforming biosimulation platforms by enabling:

• Faster model development
• Automated parameter optimization
• Improved predictive accuracy
• Complex biological system modeling
• Virtual patient simulations
• Biomarker identification
• Predictive toxicology
• Precision medicine applications

AI-powered biosimulation is helping researchers generate deeper biological insights while accelerating therapeutic innovation.

Market Challenges

Despite strong growth potential, several factors continue to limit widespread adoption.

High Implementation Costs

Deploying advanced biosimulation software often requires significant investment in:

• Specialized software platforms
• High-performance computing infrastructure
• Data management systems
• Regulatory compliance
• Employee training

These costs may present challenges for small and mid-sized biotechnology companies.

Shortage of Skilled Modeling Experts

Successful biosimulation requires multidisciplinary expertise spanning:

• Pharmacometrics
• Systems biology
• Computational chemistry
• Clinical pharmacology
• Bioinformatics
• Mathematical modeling

The limited availability of experienced professionals remains one of the industry’s major constraints.

Data Integration and Model Validation

Integrating data from laboratory research, clinical trials, genomics, proteomics, and real-world evidence can be technically challenging.

Ensuring model accuracy, reproducibility, and regulatory acceptance also requires extensive validation, making implementation more complex for many organizations.

Competitive Landscape

The biosimulation market features several established software providers and specialized computational modeling companies competing through technological innovation, strategic collaborations, acquisitions, and AI integration.

Leading market participants include:

• Certara (US)
• Dassault Systèmes (France)
• Schrödinger, Inc. (US)
• Simulations Plus (US)
• Advanced Chemistry Development (Revvity) (Canada)
• Chemical Computing Group
• Rosa & Co.
• Genedata AG (Danaher)
• Physiomics plc
• In Silico Biosciences
• OpenEye Cadence Molecular Sciences
• Insilico Medicine
• Metrum Research Group

These companies continue expanding their product portfolios by integrating artificial intelligence, cloud computing, virtual patient technologies, predictive analytics, and digital twin capabilities into biosimulation workflows.

Industry Developments

The biosimulation market continues to witness strategic collaborations aimed at accelerating innovation.

In May 2026, Certara partnered with Altasciences to combine Certara’s biosimulation and regulatory science expertise with Altasciences’ preclinical and clinical development services. The collaboration aims to optimize decision-making, reduce development risks, and accelerate early-stage drug development.

In March 2026, Simulations Plus launched strategic collaboration programs focused on integrating artificial intelligence into biosimulation workflows, enabling improved predictive modeling and faster decision-making across pharmaceutical R&D.

Company Spotlight: Certara

Certara has established itself as one of the global leaders in biosimulation through its comprehensive portfolio of model-based drug development solutions.

Its offerings include:

• Physiologically Based Pharmacokinetic (PBPK) modeling
• Quantitative Systems Pharmacology (QSP)
• Regulatory science consulting
• Dose optimization
• Safety prediction
• Clinical pharmacology modeling

The company supports pharmaceutical manufacturers, biotechnology firms, and regulatory agencies in improving development efficiency and regulatory success.

In October 2025, Certara introduced an AI-enabled QSP platform designed to automate model development, improve predictive performance, and simplify the analysis of complex biological systems. This innovation allows researchers to make faster and more informed decisions throughout the drug development process.

Company Spotlight: Dassault Systèmes

Dassault Systèmes provides biosimulation capabilities through its 3DEXPERIENCE Platform and Life Sciences Solutions Portfolio.

Its solutions enable pharmaceutical and biotechnology companies to:

• Model complex biological systems
• Perform virtual experiments
• Predict treatment outcomes
• Develop digital twins
• Reduce development risks
• Accelerate innovation

The company continues enhancing its offerings by integrating artificial intelligence, cloud-based collaboration, and virtual twin technologies while expanding its global presence through partnerships and acquisitions.

Company Spotlight: Schrödinger, Inc.

Schrödinger has developed a strong position in computational drug discovery by combining molecular modeling, machine learning, and predictive simulation technologies.

Its platform supports:

• Target identification
• Lead optimization
• Candidate selection
• Protein engineering
• Molecular design
• Clinical success prediction

In January 2026, Schrödinger partnered with Eli Lilly to integrate its TuneLab platform within the LiveDesign environment, enabling researchers to streamline protein engineering workflows and accelerate therapeutic discovery through advanced computational design.

Emerging Trends Shaping the Biosimulation Market

Several innovations are expected to redefine the future of biosimulation:

• AI-driven biosimulation platforms
• Virtual patient modeling
• Digital twin technology
• Cloud-based simulation environments
• Real-world evidence integration
• Multi-scale biological modeling
• Precision medicine applications
• Predictive toxicology
• Biomarker discovery
• Automated regulatory modeling

These advancements will help pharmaceutical companies reduce development risks while improving the efficiency and success of drug development programs.

Future Outlook

The biosimulation market is poised for sustained double-digit growth as pharmaceutical companies increasingly embrace predictive modeling to improve R&D productivity, reduce costs, and accelerate the delivery of innovative therapies.

Growing regulatory acceptance of model-informed drug development, rapid advances in artificial intelligence, increasing adoption of cloud-based simulation platforms, and expanding applications in personalized medicine will continue to reshape the future of drug development.

As organizations seek faster, more cost-effective ways to bring new medicines to market, biosimulation will remain a critical technology enabling data-driven decision-making across the global life sciences ecosystem.